Sanofi (SNY) Competitors

Sanofi has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Novartis has higher revenue and earnings than Sanofi. Novartis is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Novartis has a net margin of 23.29% compared to Sanofi's net margin of 8.66%. Novartis' return on equity of 38.56% beat Sanofi's return on equity.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.2%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis pays out 46.5% of its earnings in the form of a dividend.

Sanofi currently has a consensus price target of $49.50, suggesting a potential upside of 15.74%. Novartis has a consensus price target of $153.00, suggesting a potential upside of 11.50%. Given Sanofi's higher possible upside, research analysts clearly believe Sanofi is more favorable than Novartis.

In the previous week, Novartis had 35 more articles in the media than Sanofi. MarketBeat recorded 40 mentions for Novartis and 5 mentions for Sanofi. Sanofi's average media sentiment score of 1.32 beat Novartis' score of -0.32 indicating that Sanofi is being referred to more favorably in the media.

14.0% of Sanofi shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Astrazeneca has a net margin of 17.02% compared to Sanofi's net margin of 8.66%. Astrazeneca's return on equity of 31.45% beat Sanofi's return on equity.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.7%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Astrazeneca currently has a consensus target price of $206.67, suggesting a potential upside of 29.19%. Sanofi has a consensus target price of $49.50, suggesting a potential upside of 15.74%. Given Astrazeneca's stronger consensus rating and higher possible upside, equities analysts plainly believe Astrazeneca is more favorable than Sanofi.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Astrazeneca had 24 more articles in the media than Sanofi. MarketBeat recorded 29 mentions for Astrazeneca and 5 mentions for Sanofi. Sanofi's average media sentiment score of 1.32 beat Astrazeneca's score of 0.53 indicating that Sanofi is being referred to more favorably in the news media.

Astrazeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Astrazeneca has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

In the previous week, Novo Nordisk A/S had 50 more articles in the media than Sanofi. MarketBeat recorded 55 mentions for Novo Nordisk A/S and 5 mentions for Sanofi. Sanofi's average media sentiment score of 1.32 beat Novo Nordisk A/S's score of 0.47 indicating that Sanofi is being referred to more favorably in the news media.

Novo Nordisk A/S has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.9%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Novo Nordisk A/S currently has a consensus target price of $64.94, indicating a potential upside of 50.90%. Sanofi has a consensus target price of $49.50, indicating a potential upside of 15.74%. Given Novo Nordisk A/S's higher possible upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Novo Nordisk A/S has a net margin of 35.36% compared to Sanofi's net margin of 8.66%. Novo Nordisk A/S's return on equity of 58.61% beat Sanofi's return on equity.

Sanofi presently has a consensus target price of $49.50, suggesting a potential upside of 15.74%. Pfizer has a consensus target price of $28.39, suggesting a potential upside of 2.52%. Given Sanofi's stronger consensus rating and higher possible upside, analysts clearly believe Sanofi is more favorable than Pfizer.

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Sanofi has a net margin of 8.66% compared to Pfizer's net margin of 6.80%. Pfizer's return on equity of 19.63% beat Sanofi's return on equity.

In the previous week, Pfizer had 28 more articles in the media than Sanofi. MarketBeat recorded 33 mentions for Pfizer and 5 mentions for Sanofi. Sanofi's average media sentiment score of 1.32 beat Pfizer's score of 0.82 indicating that Sanofi is being referred to more favorably in the media.

Sanofi has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.1%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.2%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Sanofi has higher earnings, but lower revenue than Pfizer. Sanofi is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.